Shots:

• The P-III POLO study involves assessing of Lynparza (olaparib- 300mg- bid) vs PBO in 154 patients in ratio (3:2) with BRCAm metastatic pancreatic cancer whose disease had not progressed on 1st-line Pt-based CT
• The P-III POLO study results: improvement in PFS (7.4 vs 3.8mos.); @1yr & 2yrs. no disease progression ( 34% & 22% vs 15% & 10%) respectively
• Lynparza (olaparib) is a PARP inhibitor targeted for DNA damage response (DDR) pathway deficiencies- including BRCA mutations. In 2017- Merck and AstraZeneca collaborated to co-develop and co-commercialize Lynparza globally

Ref: AstraZeneca | Image: AstraZeneca